EGFR-mutated NSCLC patients treated with EGFR-TKIs
  • View Times: 15
  • |
  • Release Date: 2022-01-10
  • miRNA
  • EGFR-mutated NSCLC
  • response to EGFR-TKI
Video Introduction

This video is adapted from 10.3390/cells10061520

Resistance to EGFR-TKIs constitutes a major challenge for the management of EGFR-mutated NSCLC, and recent evidence suggests that deregulation of specific microRNAs (miRNAs) may influence resistance to targeted agents. In this video, researchers explored the role of specific plasmatic miRNAs (miR-21, miR-27a and miR-181a) as a surrogate for predicting EGFR-TKI performance in EGFR-mutated NSCLC patients.

Full Transcript


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Giovannetti, E.; Capula, M.; Minari, R.; Mazzaschi, G.; Gregori, A.; El Hassouni, B.; Papini, F.; Avan, A.; Tiseo, M. EGFR-mutated NSCLC patients treated with EGFR-TKIs. Encyclopedia. Available online: (accessed on 24 April 2024).
Giovannetti E, Capula M, Minari R, Mazzaschi G, Gregori A, El Hassouni B, et al. EGFR-mutated NSCLC patients treated with EGFR-TKIs. Encyclopedia. Available at: Accessed April 24, 2024.
Giovannetti, Elisa, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Amir Avan, Marcello Tiseo. "EGFR-mutated NSCLC patients treated with EGFR-TKIs" Encyclopedia, (accessed April 24, 2024).
Giovannetti, E., Capula, M., Minari, R., Mazzaschi, G., Gregori, A., El Hassouni, B., Papini, F., Avan, A., & Tiseo, M. (2022, January 10). EGFR-mutated NSCLC patients treated with EGFR-TKIs. In Encyclopedia.
Giovannetti, Elisa, et al. "EGFR-mutated NSCLC patients treated with EGFR-TKIs." Encyclopedia. Web. 10 January, 2022.